What is Mauna Kea Technologies?
Mauna Kea Technologies is a global leader in the medical technology landscape, specifically recognized for its pioneering work in real-time cellular imaging. The company's flagship platform, Cellvizio, provides clinicians with the ability to visualize tissue at the cellular level during endoscopic procedures. This capability is transformative for diagnostic precision, allowing for immediate, informed surgical decision-making that can significantly improve patient outcomes in complex fields such as oncology and gastroenterology. By bridging the gap between traditional imaging and histopathology, the company occupies a unique niche in the healthcare economy, providing high-value solutions that reduce diagnostic uncertainty and enhance procedural efficiency.
How much funding has Mauna Kea Technologies raised?
Mauna Kea Technologies has raised a total of $68.4M across 6 funding rounds:
Series B
$30M
Debt
$7.5M
Unspecified
$8.4M
Share Placement
$14.7M
Debt
$2.1M
Other Financing Round
$5.8M
Series B (2008): $30M with participation from Psilos Group, Creadev, and Seventure Partners
Debt (2017): $7.5M led by IPF Partners
Unspecified (2019): $8.4M supported by JJDC
Share Placement (2021): $14.7M featuring Armistice Capital and Johnson & Johnson Innovation
Debt (2025): $2.1M backed by Vester Finance
Other Financing Round (2025): $5.8M, investors not publicly disclosed
Key Investors in Mauna Kea Technologies
Psilos Group
A healthcare-focused investment firm that provides venture and growth capital to companies in the medical technology and healthcare services sectors.
Creadev
An investment company backed by the Mulliez family that supports high-potential SMEs with a focus on health, food, and climate sectors.
Seventure Partners
An active venture capital partner specializing in digital technologies and life sciences, with a strong focus on health, nutrition, and biotechnology.
What's next for Mauna Kea Technologies?
With the successful acquisition of $5.8M, Mauna Kea Technologies is well-positioned to accelerate its market penetration and R&D initiatives. The strategic focus will likely shift toward expanding the clinical utility of the Cellvizio platform, potentially integrating advanced AI-driven analytics to further enhance diagnostic accuracy. As the company navigates the complexities of the global medical device market, the continued support from institutional backers and strategic partners will be instrumental in scaling operations and securing broader regulatory adoption. Future growth will likely hinge on the company's ability to translate its technological edge into standardized clinical practice, thereby cementing its role as an essential provider of precision diagnostic tools in the modern healthcare ecosystem.
See full Mauna Kea Technologies company page
